4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by Analysts at B. Riley Financial

B. Riley Financial assumed coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research report sent to investors on Friday morning, MarketBeat.com reports. The firm issued a buy rating and a $37.00 target price on the stock.

Other equities analysts have also issued research reports about the stock. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research report on Monday, July 20th. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a report on Friday, July 17th. Finally, Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, 4D Molecular Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $30.67.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $10.18 on Friday. 4D Molecular Therapeutics has a one year low of $4.30 and a one year high of $14.00. The business’s fifty day moving average price is $10.58 and its 200-day moving average price is $9.65. The stock has a market capitalization of $532.21 million, a PE ratio of -3.96 and a beta of 2.70.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. As a group, equities analysts expect that 4D Molecular Therapeutics will post -3.8 EPS for the current fiscal year.

Insider Activity

In other 4D Molecular Therapeutics news, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider owned 942,485 shares in the company, valued at $9,867,817.95. This trade represents a 10.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 184,811 shares of company stock valued at $2,075,906. 7.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On 4D Molecular Therapeutics

A number of large investors have recently modified their holdings of the company. Dynamic Technology Lab Private Ltd bought a new stake in 4D Molecular Therapeutics during the 1st quarter worth approximately $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics in the 3rd quarter valued at $41,000. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics in the 1st quarter valued at $46,000. Daiwa Securities Group Inc. boosted its holdings in 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares during the period. Finally, Rangeley Capital LLC purchased a new position in shares of 4D Molecular Therapeutics during the 2nd quarter valued at $48,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.